Get a comprehensive report summary describing the market size and forecast along with research methodology. View our Sample Report
Autologous Cell Therapy Market 2021-2025: Scope
The autologous cell therapy market report covers the following areas:
Autologous Cell Therapy Market 2021-2025: Segmentation
- Product
- Autologous Stem Cell Therapy: The autologous stem cell therapy segment will contribute the highest market share. This segment is growing at a medium pace due to its manufacturing complexities. Vendors are conducting extensive clinical trials due to fewer complications associated with the use of autologous stem cell therapy.
- Autologous Cellular Immunotherapies
- Geography
- North America: North America will account for 43% of the market's growth during the forecast period. This growth is attributed to limitations in traditional organ transplantations, which is fueling the demand for stem cell therapies. Moreover, market growth in this region will be slower than the growth of the market in other regions. The US and Canada are the key countries for the autologous cell therapy market in North America.
- Europe
- APAC
- South America
- MEA
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report
Autologous Cell Therapy Market 2021-2025: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the autologous cell therapy market, including Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. among others. The key offerings of some of these vendors are listed below:
- Bayer AG - The company offers induced pluripotent stem cells, which are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.
- Brainstorm Cell Therapeutics Inc. - It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.
- Daiichi Sankyo Co. Ltd. - It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.
- FUJIFILM Holdings Corp. - The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.
- Holostem Terapie Avanzate Srl - It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.
Get lifetime access to our Technavio Insights! Subscribe to our "Basic Plan" billed annually at USD 5000
Autologous Cell Therapy Market 2021-2025: Key Highlights
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will assist autologous cell therapy market growth during the next five years
- Estimation of the autologous cell therapy market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the autologous cell therapy market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of autologous cell therapy market vendors
Related Reports
Hairy Cell Leukemia Therapeutics Market by Product and Geography - Forecast and Analysis 2022-2026
Cell Therapy Market by Type, Application, and Geography - Forecast and Analysis 2022-2026
Autologous Cell Therapy Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 14.16% |
Market growth 2021-2025 |
USD 4.11 billion |
Market structure |
Fragmented |
YoY growth (%) |
13.5 |
Regional analysis |
North America, Europe, APAC, and South America |
Performing market contribution |
North America at 43% |
Key consumer countries |
US, UK, Germany, Canada, and Japan |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. |
Market Dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table Of Contents :
Executive Summary
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Autologous stem cell therapy - Market size and forecast 2020-2025
- Autologous cellular immunotherapies - Market size and forecast 2020-2025
- Market opportunity by Product
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Bayer AG
- Brainstorm Cell Therapeutics Inc.
- Daiichi Sankyo Co. Ltd.
- FUJIFILM Holdings Corp.
- Holostem Terapie Avanzate Srl
- Smith and Nephew plc
- Sumitomo Chemical Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vericel Corp.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article